Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Norfloxacin Articles

18 ingredients set for OTC switch in Japan, including PPIs

11 May 2009

Black box warnings on fluoroquinolone

14 July 2008

India's Supreme Court OKs NNPA price orders

18 April 2005

Dr Reddy's sees full-year sales climb 11%

7 June 2004

India's NPPA seeks to recover millions of rupees from 50 local companies

15 September 2003

Court frees 7 drugs from India's DPCO

3 September 2001

Chinese retail drug sales "up 30% to $2.5 billion in 2000, will hit $7

27 February 2001

8 bulk drugs under price control in India

11 December 2000

Indian bulk drug firms warned on overpricing

18 September 2000

India raises prices of three bulk drugs

26 February 1999

Canadian High Court Slams Drug Laws

21 July 1998

Chinese Province Cuts Drug Prices 10%

4 June 1998

India: "Price Control On 75 More Drugs"

7 October 1997

Rhone-Poulenc Reorganizes In India

7 April 1997

Merck & Co Sues FDA, PTO Over GATT Ruling

14 August 1995

FDA Panel Turns Down Monurol NDA

31 July 1995

India Claws Back "Unintended"Profits

12 June 1995

Mixed Quarterly Results From The USA

5 June 1995

New Developments At Roberts

20 March 1995

Squeeze On Japanese Pharma Cos In First Half

21 November 1994

France Cuts Drug Prices, Bans Promo Campaigns

5 September 1994

INDIA: A PATENT REGIME FOR DRUG SECURITY

21 June 1993

QUINOLONE SAFETY NOTED BY CSM

15 March 1993

LABS LIADE BECOMES BOOTS PHARMA

27 January 1992

BANYU PINS HOPESON LIPOVAS

20 January 1992

Showing 1-25 of 25 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
  • Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • It's official: "obesity is a disease," says AMA
  • Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS